373 related articles for article (PubMed ID: 23239265)
1. Optimal management of brain metastases from breast cancer. Issues and considerations.
Bartsch R; Berghoff AS; Preusser M
CNS Drugs; 2013 Feb; 27(2):121-34. PubMed ID: 23239265
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
Morikawa A; Wang R; Patil S; Diab A; Yang J; Hudis CA; McArthur HL; Beal K; Seidman AD
Clin Breast Cancer; 2018 Oct; 18(5):353-361. PubMed ID: 29337140
[TBL] [Abstract][Full Text] [Related]
3. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
5. CNS complications of breast cancer: current and emerging treatment options.
Kaal EC; Vecht CJ
CNS Drugs; 2007; 21(7):559-79. PubMed ID: 17579499
[TBL] [Abstract][Full Text] [Related]
6. Activity of T-DM1 in Her2-positive breast cancer brain metastases.
Bartsch R; Berghoff AS; Vogl U; Rudas M; Bergen E; Dubsky P; Dieckmann K; Pinker K; Bago-Horvath Z; Galid A; Oehler L; Zielinski CC; Gnant M; Steger GG; Preusser M
Clin Exp Metastasis; 2015 Oct; 32(7):729-37. PubMed ID: 26303828
[TBL] [Abstract][Full Text] [Related]
7. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
Yomo S; Hayashi M; Cho N
J Neurooncol; 2013 Apr; 112(2):199-207. PubMed ID: 23296546
[TBL] [Abstract][Full Text] [Related]
8. Current Treatment Options for Breast Cancer Brain Metastases.
Raghunath A; Desai K; Ahluwalia MS
Curr Treat Options Oncol; 2019 Feb; 20(3):19. PubMed ID: 30771009
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
10. Local and systemic therapy in breast cancer patients with central nervous system metastases.
Wellerdieck NEA; Wessels P; Los M; Sonke GS; Tromp E; Brandsma D
Breast Cancer Res Treat; 2022 Jul; 194(2):365-384. PubMed ID: 35680734
[TBL] [Abstract][Full Text] [Related]
11. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update.
Arslan C; Dizdar O; Altundag K
Expert Opin Pharmacother; 2014 Aug; 15(12):1643-58. PubMed ID: 25032884
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
14. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.
Bartsch R; Berghoff A; Pluschnig U; Bago-Horvath Z; Dubsky P; Rottenfusser A; DeVries C; Rudas M; Fitzal F; Dieckmann K; Mader RM; Gnant M; Zielinski CC; Steger GG
Br J Cancer; 2012 Jan; 106(1):25-31. PubMed ID: 22127284
[TBL] [Abstract][Full Text] [Related]
15. Management of Brain and Leptomeningeal Metastases from Breast Cancer.
Pellerino A; Internò V; Mo F; Franchino F; Soffietti R; Rudà R
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198331
[TBL] [Abstract][Full Text] [Related]
16. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer brain metastases - A 12 year review of treatment outcomes.
De Ieso PB; Schick U; Rosenfelder N; Mohammed K; Ross GM
Breast; 2015 Aug; 24(4):426-33. PubMed ID: 25881974
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of human epidermal growth factor receptor 2 status and systemic therapy in breast cancer with brain metastases treated with radiotherapy.
Tsuruoka S; Kataoka M; Uwatsu K; Makita K; Tsuruoka K; Takata N; Ishikawa H; Hamamoto Y; Mochizuki T; Kido T
Asia Pac J Clin Oncol; 2023 Jun; 19(3):347-354. PubMed ID: 36281655
[TBL] [Abstract][Full Text] [Related]
19. Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.
Kingston B; Kayhanian H; Brooks C; Cox N; Chaabouni N; Redana S; Kalaitzaki E; Smith I; O'Brien M; Johnston S; Parton M; Noble J; Stanway S; Ring A; Turner N; Okines A
Breast; 2017 Dec; 36():54-59. PubMed ID: 28968585
[TBL] [Abstract][Full Text] [Related]
20. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
